US2014155587A1PendingUtilityA1
Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Est. expiryJun 28, 2024(expired)· nominal 20-yr term from priority
A61P 21/00C12N 2310/315C12N 2310/11C12N 2320/30C12N 15/113C12N 2310/3519C12N 2320/33C12N 2310/3233C12N 2310/321C12N 2310/33C12N 2310/3341
72
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202.
Claims
exact text as granted — not AI-modified1 . (canceled)
2 . An isolated antisense oligonucleotide of 20 to 50 nucleotides in length, said oligonucleotide comprising a nucleotide sequence which is complementary to a target sequence of exon 51 of the human dystrophin pre-mRNA, wherein said target sequence comprises a nucleotide sequence that is complementary to the sequence ACA UCA AGG AAG AUG GCA UUU CUA G (SEQ ID NO: 180), and wherein said oligonucleotide comprises a morpholine ring.
3 . An isolated antisense oligonucleotide of 20 to 50 nucleotides in length, said oligonucleotide comprising a nucleotide sequence which is complementary to a target sequence of exon 51 of the human dystrophin pre-mRNA, wherein said target sequence comprises a nucleotide sequence that is complementary to the sequence ACA UCA AGG AAG AUG GCA UUU CUA G (SEQ ID NO: 180), and wherein said oligonucleotide comprises a peptide nucleic acid and/or locked nucleic acid.
4 . An isolated antisense oligonucleotide of 20 to 50 nucleotides in length, said oligonucleotide comprising a nucleotide sequence which is complementary to a target sequence of exon 51 of the human dystrophin pre-mRNA, wherein said target sequence comprises a nucleotide sequence that is complementary to the sequence ACA UCA AGG AAG AUG GCA UUU CUA G (SEQ ID NO: 180), and wherein said oligonucleotide comprises a 2′-O-methyl ribose moiety.
5 . The oligonucleotide of claim 2 , wherein said oligonucleotide further comprises a phosphorodiamidate internucleoside linkage.
6 . The oligonucleotide of claim 5 , wherein each linkage is a phosphorodiamidate internucleoside linkage.
7 . The oligonucleotide of claim 6 , wherein the oligonucleotide is a morpholino phosphorodiamidate oligonucleotide.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.